In addition to directly inhibiting tumor cell proliferation, GHRH antagonists reduce the secretion of growth factors such as IGF-1, VEGF, and pro-inflammatory cytokines, which are essential for tumor angiogenesis and metastasis [8, 9, 60, 61]. The gene discussed is IGF1; the disease is neoplasm.